Neuroblastoma: issues in transplantation.
作者信息
Grupp Stephan A, Asgharzadeh Shahab, Yanik Gregory A
机构信息
Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.
出版信息
Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S92-100. doi: 10.1016/j.bbmt.2011.10.020.
Abstract
摘要
相似文献
1
Neuroblastoma: issues in transplantation.
Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S92-100. doi: 10.1016/j.bbmt.2011.10.020.
2
Impact of myeloablative therapy with bone marrow transplantation in advanced neuroblastoma.
Bone Marrow Transplant. 1996 Dec;18 Suppl 3:S21-4.
3
131I-Metaiodobenzylguanidine conditioning regimen in children with neuroblastoma undergoing stem cell transplantation.
Pediatr Transplant. 2013 Jun;17(4):407-8. doi: 10.1111/petr.12087.
4
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.
Lancet Oncol. 2005 Sep;6(9):649-58. doi: 10.1016/S1470-2045(05)70291-6.
5
Chemo-radiotherapy and autologous bone marrow transplantation in poor prognosis neuroblastoma.
Radiother Oncol. 1990;18 Suppl 1:102-4. doi: 10.1016/0167-8140(90)90185-y.
6
Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.
N Engl J Med. 1999 Oct 14;341(16):1165-73. doi: 10.1056/NEJM199910143411601.
7
Autologous stem cell transplantation following high-dose chemotherapy in children with high-risk neuroblastoma: Practicality in resource-limited countries.
Pediatr Blood Cancer. 2020 May;67(5):e28176. doi: 10.1002/pbc.28176. Epub 2020 Jan 21.
8
A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
Bone Marrow Transplant. 1996 Jun;17(6):911-6.
9
Bone marrow transplantation (BMT) for advanced neuroblastoma (NBL): a multicenter POG pilot study.
Prog Clin Biol Res. 1988;271:215-23.
10
Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies.
J Clin Oncol. 1996 Sep;14(9):2417-26. doi: 10.1200/JCO.1996.14.9.2417.
引用本文的文献
1
Cancer stem cells in neuroblastoma therapy resistance.
Cancer Drug Resist. 2019 Dec 19;2(4):948-967. doi: 10.20517/cdr.2019.72. Epub 2019 Nov 11.
2
-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-G immunotherapy.
Oncotarget. 2017 Aug 24;8(56):95293-95302. doi: 10.18632/oncotarget.20513. eCollection 2017 Nov 10.
3
Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.
Biol Blood Marrow Transplant. 2017 Nov;23(11):1910-1917. doi: 10.1016/j.bbmt.2017.07.011. Epub 2017 Jul 18.
4
Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Oncotarget. 2016 Jan 26;7(4):4155-66. doi: 10.18632/oncotarget.6393.
5
Neuroblastoma: developmental biology, cancer genomics and immunotherapy.
Nat Rev Cancer. 2013 Jun;13(6):397-411. doi: 10.1038/nrc3526.
本文引用的文献
1
The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma.
Eur J Cancer. 2011 May;47(8):1193-202. doi: 10.1016/j.ejca.2011.02.003. Epub 2011 Mar 21.
2
Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.
Pediatr Blood Cancer. 2011 Jul 1;56(7):1041-5. doi: 10.1002/pbc.22991. Epub 2011 Feb 15.
3
Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials.
Pediatr Blood Cancer. 2011 Apr;56(4):578-83. doi: 10.1002/pbc.22693. Epub 2010 Dec 9.
4
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.
BMC Cancer. 2011 Jan 18;11:21. doi: 10.1186/1471-2407-11-21.
5
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
N Engl J Med. 2010 Sep 30;363(14):1324-34. doi: 10.1056/NEJMoa0911123.
6
Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.
N Engl J Med. 2010 Sep 30;363(14):1313-23. doi: 10.1056/NEJMoa1001527.
7
Global genomic and RNA profiles for novel risk stratification of neuroblastoma.
Cancer Sci. 2010 Nov;101(11):2295-301. doi: 10.1111/j.1349-7006.2010.01681.x.
8
Prognostic impact of gene expression-based classification for neuroblastoma.
J Clin Oncol. 2010 Jul 20;28(21):3506-15. doi: 10.1200/JCO.2009.27.3367. Epub 2010 Jun 21.
9
Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.
Clin Cancer Res. 2010 Mar 1;16(5):1532-41. doi: 10.1158/1078-0432.CCR-09-2607. Epub 2010 Feb 23.
10
Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.
Clin Chem. 2009 Jul;55(7):1316-26. doi: 10.1373/clinchem.2008.117945. Epub 2009 May 21.
Zotero 插件